Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Tirzepatide

Mounjaro, Zepbound, LY3298176

Quick Stats
Studies 183
Trials 100
Completed OBSERVATIONAL NCT06761703

A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.

Interventions

Name: TAP® Micro Select Device (Touch Activated Phlebotomy)
Type: DEVICE
Description: The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.

Primary Outcomes

Measure: Number of Participants with Self-blood Draw Received by Central Laboratory
TimeFrame: 30 days
Description:

Trial Information

NCT ID

NCT06761703

Status

Completed

Study Type

OBSERVATIONAL

Sponsor

Amgen

Last Updated

December 15, 2025

Related Peptides